Lataa...
Androgen Receptor Burden and Poor Response to Abiraterone or Enzalutamide in TP53 Wild-Type Metastatic Castration-Resistant Prostate Cancer
This post hoc analysis of a multi-institution cohort study assesses the association between androgen receptor perturbation and poorer outcome in patients with TP53 wild-type metastatic castration-resistant prostate cancer who are receiving abiraterone or enzalutamide.
Tallennettuna:
| Julkaisussa: | JAMA Oncol |
|---|---|
| Päätekijät: | , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
American Medical Association
2019
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6499126/ https://ncbi.nlm.nih.gov/pubmed/31046065 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2019.0869 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|